Glythera is a biotechnology company specializing in the development of next generation therapeutics through the application of its linker and stable glycan technologies PermaLink™ and PermaCarb™.
These technologies offer improved stability, bioavailability and efficiency in oncology and therapeutics applications.
We are open to opportunities for technology out-licensing, collaboration or provision of full service business models for the use of PermaLink™ or PermaCarb™.
If you are looking to improve control, efficiency and post-transitional modification in the development of protein conjugates and biotherapeutics then our dedicated team would be happy to discuss the opportunities with you.
Herschel Annex, King's Road, Newcastle-upon-Tyne
NE1 7RU, UK.